Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M9466 Alone or in Combination in Advanced Solid Tumors
NCT06421935Phase 1Active, not recruiting
- Sponsor
- EMD Serono
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of M9466 in solid tumor, prostate cancer (PCa) and ovarian cancer (3 arms), sponsored by EMD Serono. Primary endpoints: Treatment-Emergent Adverse Events at 20 months, Dose Limiting Toxicities at 21 days and 1 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
M9466
03
Conditions
solid tumorprostate cancer (PCa)ovarian cancer
Beyond the preview
Go deeper on NCT06421935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421935.